In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $67.21, marking a +1.04% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.58% for the day ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $72.31, demonstrating a -2.24% change from the preceding day's closing price. Elsewhere, the Dow saw an upswing of 0.47%, while the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Intellia Therapeutics said it is pausing two late-stage CRISPR gene-editing trials after a patient in one study was hospitalized with liver damage.

CRISPR Therapeutics (CRSP) has filed a prospectus supplement with the U.S. SEC to sell up to $600 million worth of its common ...

Crispr Therapeutics maintains leadership in gene editing, with shares up 75% YTD and renewed investor interest after positive CTX-310 data. CRSP's in-vivo therapy shows promising early results, ...